Analysis of the transcription regulator, CNOT7, as a candidate chromosome 8 tumor suppressor gene in colorectal cancer

International Journal of Cancer

Volumn 106, Issue 4, 2003, Pages 505-509

  Flanagan, James ^a   Healey, Sue ^a   Young, Joanne ^a   Whitehall, Vicki ^a   Chenevix Trench, Georgia ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

8p22; CNOT7; Colorectal cancer; Denaturing high performance liquid chromatography (DHPLC); Loss of heterozygosity (LOH); Somatic mutation

Indexed keywords

CHEMOKINE RECEPTOR CCR4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CNOT7; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 8; CHROMOSOME MAP; COLON MUCOSA; COLORECTAL CANCER; COMPLEX FORMATION; CONTROLLED STUDY; CRYPT CELL; GENE EXPRESSION; GENETIC CODE; HETEROZYGOSITY LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 8; COLON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; DNA-BINDING PROTEINS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0043095372     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11264     Document Type: Article

References (45)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
2. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998;42:673-9.
3. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
4. Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:335-51.
5. Gustafson CE, Wilson PJ, Lukeis R, Baker E, Woollatt E, Annab L, Hawke L, Barrett JC, Chenevix-Trench G. Functional evidence for a colorectal cancer tumor suppressor gene at chromosome 8p22-23 by monochromosome transfer. Cancer Res 1996;56:5238-45.
6. Farrington SM, Cunningham C, Boyle SM, Wyllie AH, Dunlop MG. Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumor suppressor loci involved in colorectal cancer. Oncogene 1996;12:1803-8.
7. Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, Buecher B, Martinet N, Galateau F, Thomas G. Fine deletion mapping of chromosome 8p in non-small-cell lung carcinoma. Int J Cancer 1999;81:854-8.
8. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig TE, Farr GH, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer lnst 1999;91:1295-303.
9. Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh J, Nosrati A, Willson JK, Mack D, Ried T, Markowitz S. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002;62:1134-8.
10. Wright K, Wilson PJ, Kerr J, Do K, Hurst T, Khoo SK, Ward B, Chenevix-Trench G. Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 1998;17:1185-8.
11. Prasad MA, Trybus TM, Wojno KJ, Macoska JA. Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site. Genes Chromosomes Cancer 1998;23:255-62.
12. Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999;59:1973-9.
13. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
14. Hamaguchi M, Meth JL, Von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 2002;99:13647-52.
15. Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM, Baffa R. Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res 2001;7:1546-52.
16. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci USA 2001;98:10374-9.
17. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 2001;20:4169-79.
18. Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM, Baffa R. FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 2002;160:1345-52.
19. Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 2002;8:2292-7.
20. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001;107:347-59.
21. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000;32(Pt 1):721-7.
22. Wilson PJ, McGlinn E, Marsh A, Evans T, Arnold J, Wright K, Biden K, Young J, Wainwright B, Wicking C, Chenevix-Trench G. Sequence variants of DLC1 in colorectal and ovarian tumors. Hum Mutat 2000;15:156-65.
23. Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, Nakamura Y. Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. Oncogene 1995;10:891-5.
24. Hampsey M. Molecular genetics of the RNA polymerase II general transcriptional machinery. Microbiol Mol Biol Rev 1998;62:465-503.
25. Lee TI, Wyrick JJ, Koh SS, Jennings EG, Gadbois EL, Young RA. Interplay of positive and negative regulators in transcription initiation by RNA polymerase II holoenzyme. Mol Cell Biol 1998;18:4455-62.
26. Badarinarayana V, Chiang YC, Denis CL. Functional interaction of CCR4-NOT proteins with TATAA-binding protein (TBP) and its associated factors in yeast. Genetics 2000;155:1045-54.
27. Lenssen E, Oberholzer U, Labarre J, De Virgilio C, Collart MA. Saccharomyces cerevisiae Ccr4-not complex contributes to the control of Msn2p-dependent transcription by the Ras/cAMP pathway. Mol Microbiol 2002;43:1023-37.
28. Albert TK, Lemaire M, van Berkum NL, Gentz R, Collart MA, Timmers HT. Isolation and characterization of human orthologs of yeast CCR4-NOT complex subunits. Nucleic Acids Res 2000;28:809-17.
29. Bogdan JA, Adams Burton C, Pedicord DL, Sukovich DA, Benfield PA, Corjay MH, Stoltenborg JK, Dicker IB. Human carbon catabolite repressor protein (CCR4)-associative factor 1: cloning, expression and characterization of its interaction with the B-cell translocation protein BTG1. Biochem J 1998;336(Pt 2):471-81.
30. Prevot D, Morel AP, Voeltzel T, Rostan MC, Rimokh R, Magaud JP, Corbo L. Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway. J Biol Chem 2001;276:9640-8.
31. Fidler C. Wainscoat JS, Boultwood J. The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q-syndrome. Genomics 1999;56:134-6.
32. Tsai MH, Yang YC, Chen KH, Jiang JK, Chou SJ, Chiang TC, Jan HS, Lou MA. RER and LOH association with sporadic colorectal cancer in Taiwanese patients. Hepato-Gastroenterology 2002;49:672-7.
33. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996;56:2411-6.
34. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
35. Whitehead RH, Brown A, Bhathal PS. A method for the isolation and culture of human colonic crypts in collagen gels. In Vitro Cell Devel Biol 1987;23:436-42.
36. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
37. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Meth Mol Biol 2000;132:365-86.
38. Roncucci L. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma. Italian J Gastroenterol 2000;24:498-501.
39. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-8.
40. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4:802-7.
41. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kipl is haplo-insufficient for tumor suppression. Nature 1998;396:177-80.
42. Worm J, Bartkova J, Kirkin AF, Straten P, Zeuthen J, Bartek J, Guldberg P. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 2000;19:5111-5.
43. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998;17:4657-67.
44. Fairbrother WG, Yeh RF, Sharp PA, CB. Predictive identification of exonic splicing enhancers in human genes. Science 2002;297:1007-13.
45. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002;3:285-98.